US 12,465,639 B2
Modified oncolytic virus
Robert Stuart Coffin, London (GB)
Assigned to Replimune Limited GB, Oxfordshire (GB)
Filed by Replimune Limited, Oxfordshire (GB)
Filed on Sep. 6, 2023, as Appl. No. 18/462,133.
Application 18/462,133 is a continuation of application No. 17/817,245, filed on Aug. 3, 2022.
Application 17/817,245 is a continuation of application No. 16/799,090, filed on Feb. 24, 2020, granted, now 11,427,810, issued on Aug. 30, 2022.
Application 16/799,090 is a continuation of application No. 16/068,816, granted, now 10,612,005, issued on Apr. 7, 2020, previously published as PCT/GB2017/050036, filed on Jan. 9, 2017.
Claims priority of application No. 1600380 (GB), filed on Jan. 8, 2016; application No. 1600381 (GB), filed on Jan. 8, 2016; and application No. 1600382 (GB), filed on Jan. 8, 2016.
Prior Publication US 2024/0018488 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 35/763 (2015.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01); C07K 14/535 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 35/763 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); C07K 14/535 (2013.01); C07K 16/2818 (2013.01); C12N 7/00 (2013.01); A61K 2039/505 (2013.01); C12N 2710/16621 (2013.01); C12N 2710/16622 (2013.01); C12N 2710/16632 (2013.01); C12N 2710/16633 (2013.01); C12N 2710/16643 (2013.01); C12N 2740/13022 (2013.01)] 26 Claims
 
1. An oncolytic herpes simplex virus (HSV) comprising inserted in its genome: (i) a heterologous gene encoding a fusogenic glycoprotein from gibbon ape leukemia virus (GALV) from which the R peptide has been mutated or removed (GALV-R-), (ii) a heterologous gene encoding an anti-CTLA-4 antibody or an antigen binding fragment thereof, and (iii) one or more heterologous genes encoding any of a CD40 ligand, 4-1-BB ligand, GITR ligand, OX40 ligand, ICOS ligand and flt3 ligand.